NCT01667718

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

Levofloxacin-containing Therapy for Helicobacter Pylori Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 161 (actual)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.

Detailed description

The success rate of the standard triple therapy for H. pylori infection is decreasing recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.

Conditions

• Functional Dyspepsia
• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	Bismuth	Bismuth 220mg b.i.d for 2 weeks
DRUG	Lansoprazole	Lansoprazole 30 mg b.i.d.for 2 weeks
DRUG	Levofloxacin	Levofloxacin 0.5 q.d. for 2 weeks
DRUG	Amoxicillin	Amoxicillin 1 g b.i.d. for 2 weeks

Timeline

• Start date: 2012-05-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2012-08-17
• Last updated: 2012-12-13

Locations

1 site across 1 country: China